Gp96-therapy of metastatic disease.
Start of treatment post-tumor challenge (day)
Disease-incidence in mice treated with
Buffer
D122-gp96
Liver-gp96
29
89% (8/9)
0% (0/10)
44% (4/9)
31
100% (10/10)
55% (5/9)
33
100% (9/9)
40% (4/10)
Copyright © 2001 by Rajiv Chandawarkar
